Tags

Type your tag names separated by a space and hit enter

An evaluation of oral and nasal midazolam for pediatric dental sedation.
ASDC J Dent Child. 1994 May-Jun; 61(3):175-81.AJ

Abstract

Midazolam is a new short-acting benzodiazepine which is more potent than diazepam. Reports on its use in young pediatric dental patients is lacking in the literature. The purpose of this study was to evaluate the sedative qualities of midazolam via the oral and nasal routes in 100 recalcitrant pediatric dental patients between 1.5 and 6 years of age. One half of the patients received oral midazolam at a dose of 0.5 mg/kg administered with 25 mg hydroxyzine pamoate suspension as a vehicle. The other half received nasal midazolam at a dose of 0.2 mg/kg. Nitrous oxide-oxygen inhalation and local anesthesia were used in all cases. The results indicated that a satisfactory level of sedation was achieved in approximately two thirds of the cases. Complications were rare, and not of clinical significance. There was no significant difference in the frequency of success or complications reported between the oral and nasal routes. The results of the present study support the need for future investigations to determine optimal pediatric dosages and regimens for each route.

Authors+Show Affiliations

Department of Pediatric Dentistry, University of Florida College of Dentistry, Gainesville 2610-0426.No affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Review

Language

eng

PubMed ID

8089345

Citation

Hartgraves, P M., and R E. Primosch. "An Evaluation of Oral and Nasal Midazolam for Pediatric Dental Sedation." ASDC Journal of Dentistry for Children, vol. 61, no. 3, 1994, pp. 175-81.
Hartgraves PM, Primosch RE. An evaluation of oral and nasal midazolam for pediatric dental sedation. ASDC J Dent Child. 1994;61(3):175-81.
Hartgraves, P. M., & Primosch, R. E. (1994). An evaluation of oral and nasal midazolam for pediatric dental sedation. ASDC Journal of Dentistry for Children, 61(3), 175-81.
Hartgraves PM, Primosch RE. An Evaluation of Oral and Nasal Midazolam for Pediatric Dental Sedation. ASDC J Dent Child. 1994 May-Jun;61(3):175-81. PubMed PMID: 8089345.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - An evaluation of oral and nasal midazolam for pediatric dental sedation. AU - Hartgraves,P M, AU - Primosch,R E, PY - 1994/5/1/pubmed PY - 1994/5/1/medline PY - 1994/5/1/entrez SP - 175 EP - 81 JF - ASDC journal of dentistry for children JO - ASDC J Dent Child VL - 61 IS - 3 N2 - Midazolam is a new short-acting benzodiazepine which is more potent than diazepam. Reports on its use in young pediatric dental patients is lacking in the literature. The purpose of this study was to evaluate the sedative qualities of midazolam via the oral and nasal routes in 100 recalcitrant pediatric dental patients between 1.5 and 6 years of age. One half of the patients received oral midazolam at a dose of 0.5 mg/kg administered with 25 mg hydroxyzine pamoate suspension as a vehicle. The other half received nasal midazolam at a dose of 0.2 mg/kg. Nitrous oxide-oxygen inhalation and local anesthesia were used in all cases. The results indicated that a satisfactory level of sedation was achieved in approximately two thirds of the cases. Complications were rare, and not of clinical significance. There was no significant difference in the frequency of success or complications reported between the oral and nasal routes. The results of the present study support the need for future investigations to determine optimal pediatric dosages and regimens for each route. SN - 1945-1954 UR - https://www.unboundmedicine.com/medline/citation/8089345/An_evaluation_of_oral_and_nasal_midazolam_for_pediatric_dental_sedation_ DB - PRIME DP - Unbound Medicine ER -